Celebrex, Bextra Stabilizing After FDA Advisory Committee Review, Pfizer Says

Company is predicting a return to growth in the COX-2 category once FDA completes work on new labeling. Celebrex and Bextra "will remain critical treatment options for many years to come," Pfizer tells analysts.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet